Ursodeoxycholic Acid Market Synopsis
Ursodeoxycholic Acid Market Size Was Valued at USD 389.5 Billion in 2023, and is Projected to Reach USD 1,020.9 Billion by 2032, Growing at a CAGR of 11.3% From 2024-2032.
Ursodeoxycholic Acid (UDCA) market refers to products and services with regards to the production, distribution, and consumption of ursodeoxycholic acid, a secondary bile acid with pharmaceutical application for the treatment of liver and gallbladder disorders. First of all, it works well for treating gallstones and various diseases of the liver, including primary biliary cirrhosis and primary sclerosing cholangitis. The market is fueled by available data that indicate increasing rates of liver ailment, greater consciousness about protective hepatic medications, and the expanding use of UDCA in the formulation of drugs in the pharmaceutical sector.
The market for Ursodeoxycholic Acid is expected to grow due to higher demand for health care solutions for the liver diseases. The rising incidence of developing gallstones in aging population groups as well as in patient groups within elevated cholesterol levels also drive the need for maintaining UDCA based therapies. Further, due to increased incidences of NAFLD and its consequential complication including cirrhosis, ursodeoxycholic acid remains a crucial medication usable in the treatment of the condition. In addition, growth in the clinical utilization of UDCA and other related drugs is increasing to other areas, such as the treatment of liver-transplant recipients.
The market is also receiving a boost from new developments in formulation as well as improvements to the manufacturing and packaging of ursodeoxycholic acid. Currently, drug makers are investing in research the farther utilization of UDCA, either as a stand alone treatment or in combination with other drugs to improve analys treatments. This is backed by rising technology advancement in relations to collaborations between research institutes and industries players in an attempt to look for other uses of UDCA apart from the three standard uses hence driving the UDCA market.
Ursodeoxycholic Acid Market Trend Analysis:
Growing Global Interest on Minimally Invasive Procedures
-
The most influential factor that has been spearheading the growth of the Ursodeoxycholic Acid market is the need to have natural solution to diseases through medical treatment without focusing more on surgery such as gallstones diseases and some liver ailments. In contrast to common cholecystectomy procedures for gallstones, UDCA works for dissolving cholesterol stones gradually. This trend of utilizing minimally invasive procedures is gradually gaining grounds within the overall global healthcare sector as patients and their physicians consider or aim to minimize turnaround times and seek maximum patients’ safety. Consequently the use of UDCA has been increasing not only as a therapy for the treatment of gallstones but also for the chronic liver diseases.
The second strategic growth opportunity at the dispersed Index Company is the new/emerging markets
-
Current market development of Ursodeoxycholic Acid suggests considerable market growth potential in emerging regions such as Asia-Pacific and Latin America. All these regions are experiencing enhancement of health care facilities, enhanced access to drugs, and rising consciousness of liver associated disorders.
- Also, growing incidencies of lifestyle diseases that cause liver and gallbladder related issues have continued to fuel demand of products that contain UDCA. Market players are identifying new opportunities in these regions by entering into partnerships with the local distributors and healthcare providers so as to increase market access.
Ursodeoxycholic Acid Market Segment Analysis:
Ursodeoxycholic Acid Market Segmented on the basis of type, Indication, and Region.
By Type, Tablet segment is expected to dominate the market during the forecast period
-
In terms of offering, market for Ursodeoxycholic Acid split into formulations such as capsule, tablet and solution and out of these tablet formulations is expected to exhibit major market share in the coming years. Orally administered tablets are relished by patients as well as health care practitioners because of their ease in administration, accurate dosing and long-term therapeutic tablets.
- This segment largely consists of increasing proportions of generic and branded tablet formulations besides being more patient compliant making their market share outstanding. Furthermore, continued enhancements in techniques of oral drug delivery for UDCA are helping increase efficacy and ease of consumption of tablets, which in turn contributes much to the supremacy of this segment.
By Indication, the Gallstones segment is expected to held the largest share
-
By the segmentation of the product the Gallstones segment is expected to contribute the largest market share in the overall market for Ursodeoxycholic Acid. This can be blamed on the high rate of gallstone disease that is prevalent all over the world areas of high cholesterol regime and obesity. UDCA is currently used for the treatment of cholesterol gallstones that puts less strain on the patient than surgery. The continuously rising use of UDCA in the graft prevention from gallstone formation after operation and in patients with the possibility of gallstone formation caused by rapid weight loss also has a lot to do with the market share of this application segment.
Ursodeoxycholic Acid Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
-
The current market trend indicates that North America possesses the largest share of the Ursodeoxycholic Acid market, in 2023. High level of healthcare facilities along with awareness towards Liver related diseases along with Advanced diagnosis facilities leads the region towards UDCA based Treatments. The major reasons for high market domination by the US include a large patient base with liver diseases, a high incidence of gallstones, and huge health-care expenditures. Ursodeoxycholic Acid market in North America is forecasted to account for about 40% of the worldwide share in 2023. Continued backing by governments of countries in the region towards investigation on liver diseases and enhanced access to technological drugs also complement the region’s trends of this market.
Active Key Players in the Ursodeoxycholic Acid Market:
-
ABITEC Corporation (U.S.)
- Biotavia Labs (India)
- Changde Yungang Biotechnology Co., Ltd. (China)
- Daewoong Pharmaceutical (South Korea)
- Dipharma Francis (Italy)
- Erregierre (Italy)
- Grindeks (Latvia)
- ICE S.p.A (Italy)
- Lannett Company (U.S.)
- Mitsubishi Tanabe Pharma (Japan)
- PharmaZell (Germany)
- Shanghai Pharma Group (China)
- Suzhou Tianlu Bio-pharmaceutical Co., Ltd. (China)
- Teva Pharmaceutical Industries (Israel)
- Zambon S.p.A (Italy)
- Other Active Players
|
Global Ursodeoxycholic Acid Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 389.5 Billion |
|
Forecast Period 2024-32 CAGR: |
11.3 % |
Market Size in 2032: |
USD 1,020.9 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Indication |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Ursodeoxycholic Acid Market by Type
4.1 Ursodeoxycholic Acid Market Snapshot and Growth Engine
4.2 Ursodeoxycholic Acid Market Overview
4.3 Tablet
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Tablet: Geographic Segmentation Analysis
4.4 Capsule)
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Capsule): Geographic Segmentation Analysis
4.5 Indication (Gallstones
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Indication (Gallstones: Geographic Segmentation Analysis
4.6 Hepatopathy
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Hepatopathy: Geographic Segmentation Analysis
4.7 Biliary Disease
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Biliary Disease: Geographic Segmentation Analysis
4.8 Primary Biliary Cholangitis (PBC)
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Primary Biliary Cholangitis (PBC): Geographic Segmentation Analysis
4.9 Other Indications)
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Other Indications) : Geographic Segmentation Analysis
Chapter 5: Company Profiles and Competitive Analysis
5.1 Competitive Landscape
5.1.1 Competitive Benchmarking
5.1.2 Ursodeoxycholic Acid Market Share by Manufacturer (2023)
5.1.3 Industry BCG Matrix
5.1.4 Heat Map Analysis
5.1.5 Mergers and Acquisitions
5.2 DAEWOONG PHARMACEUTICAL
5.2.1 Company Overview
5.2.2 Key Executives
5.2.3 Company Snapshot
5.2.4 Role of the Company in the Market
5.2.5 Sustainability and Social Responsibility
5.2.6 Operating Business Segments
5.2.7 Product Portfolio
5.2.8 Business Performance
5.2.9 Key Strategic Moves and Recent Developments
5.2.10 SWOT Analysis
5.3 MITSUBISHI TANABE PHARMA
5.4 ICE S.P.A
5.5 PHARMAZELL
5.6 SUZHOU TIANLU BIO-PHARMACEUTICAL
5.7 OTHER ACTIVE PLAYERS
Chapter 6: Global Ursodeoxycholic Acid Market By Region
6.1 Overview
6.2. North America Ursodeoxycholic Acid Market
6.2.1 Key Market Trends, Growth Factors and Opportunities
6.2.2 Top Key Companies
6.2.3 Historic and Forecasted Market Size by Segments
6.2.4 Historic and Forecasted Market Size By Type
6.2.4.1 Tablet
6.2.4.2 Capsule)
6.2.4.3 Indication (Gallstones
6.2.4.4 Hepatopathy
6.2.4.5 Biliary Disease
6.2.4.6 Primary Biliary Cholangitis (PBC)
6.2.4.7 Other Indications)
6.2.5 Historic and Forecast Market Size by Country
6.2.5.1 US
6.2.5.2 Canada
6.2.5.3 Mexico
6.3. Eastern Europe Ursodeoxycholic Acid Market
6.3.1 Key Market Trends, Growth Factors and Opportunities
6.3.2 Top Key Companies
6.3.3 Historic and Forecasted Market Size by Segments
6.3.4 Historic and Forecasted Market Size By Type
6.3.4.1 Tablet
6.3.4.2 Capsule)
6.3.4.3 Indication (Gallstones
6.3.4.4 Hepatopathy
6.3.4.5 Biliary Disease
6.3.4.6 Primary Biliary Cholangitis (PBC)
6.3.4.7 Other Indications)
6.3.5 Historic and Forecast Market Size by Country
6.3.5.1 Russia
6.3.5.2 Bulgaria
6.3.5.3 The Czech Republic
6.3.5.4 Hungary
6.3.5.5 Poland
6.3.5.6 Romania
6.3.5.7 Rest of Eastern Europe
6.4. Western Europe Ursodeoxycholic Acid Market
6.4.1 Key Market Trends, Growth Factors and Opportunities
6.4.2 Top Key Companies
6.4.3 Historic and Forecasted Market Size by Segments
6.4.4 Historic and Forecasted Market Size By Type
6.4.4.1 Tablet
6.4.4.2 Capsule)
6.4.4.3 Indication (Gallstones
6.4.4.4 Hepatopathy
6.4.4.5 Biliary Disease
6.4.4.6 Primary Biliary Cholangitis (PBC)
6.4.4.7 Other Indications)
6.4.5 Historic and Forecast Market Size by Country
6.4.5.1 Germany
6.4.5.2 UK
6.4.5.3 France
6.4.5.4 The Netherlands
6.4.5.5 Italy
6.4.5.6 Spain
6.4.5.7 Rest of Western Europe
6.5. Asia Pacific Ursodeoxycholic Acid Market
6.5.1 Key Market Trends, Growth Factors and Opportunities
6.5.2 Top Key Companies
6.5.3 Historic and Forecasted Market Size by Segments
6.5.4 Historic and Forecasted Market Size By Type
6.5.4.1 Tablet
6.5.4.2 Capsule)
6.5.4.3 Indication (Gallstones
6.5.4.4 Hepatopathy
6.5.4.5 Biliary Disease
6.5.4.6 Primary Biliary Cholangitis (PBC)
6.5.4.7 Other Indications)
6.5.5 Historic and Forecast Market Size by Country
6.5.5.1 China
6.5.5.2 India
6.5.5.3 Japan
6.5.5.4 South Korea
6.5.5.5 Malaysia
6.5.5.6 Thailand
6.5.5.7 Vietnam
6.5.5.8 The Philippines
6.5.5.9 Australia
6.5.5.10 New Zealand
6.5.5.11 Rest of APAC
6.6. Middle East & Africa Ursodeoxycholic Acid Market
6.6.1 Key Market Trends, Growth Factors and Opportunities
6.6.2 Top Key Companies
6.6.3 Historic and Forecasted Market Size by Segments
6.6.4 Historic and Forecasted Market Size By Type
6.6.4.1 Tablet
6.6.4.2 Capsule)
6.6.4.3 Indication (Gallstones
6.6.4.4 Hepatopathy
6.6.4.5 Biliary Disease
6.6.4.6 Primary Biliary Cholangitis (PBC)
6.6.4.7 Other Indications)
6.6.5 Historic and Forecast Market Size by Country
6.6.5.1 Turkiye
6.6.5.2 Bahrain
6.6.5.3 Kuwait
6.6.5.4 Saudi Arabia
6.6.5.5 Qatar
6.6.5.6 UAE
6.6.5.7 Israel
6.6.5.8 South Africa
6.7. South America Ursodeoxycholic Acid Market
6.7.1 Key Market Trends, Growth Factors and Opportunities
6.7.2 Top Key Companies
6.7.3 Historic and Forecasted Market Size by Segments
6.7.4 Historic and Forecasted Market Size By Type
6.7.4.1 Tablet
6.7.4.2 Capsule)
6.7.4.3 Indication (Gallstones
6.7.4.4 Hepatopathy
6.7.4.5 Biliary Disease
6.7.4.6 Primary Biliary Cholangitis (PBC)
6.7.4.7 Other Indications)
6.7.5 Historic and Forecast Market Size by Country
6.7.5.1 Brazil
6.7.5.2 Argentina
6.7.5.3 Rest of SA
Chapter 7 Analyst Viewpoint and Conclusion
7.1 Recommendations and Concluding Analysis
7.2 Potential Market Strategies
Chapter 8 Research Methodology
8.1 Research Process
8.2 Primary Research
8.3 Secondary Research
|
Global Ursodeoxycholic Acid Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 389.5 Billion |
|
Forecast Period 2024-32 CAGR: |
11.3 % |
Market Size in 2032: |
USD 1,020.9 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Indication |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
